Common Blood Tests Predict CAR T-cell Therapy Response in Non-Hodgkin Lymphoma

Major Finding: An inflammatory signature is a prognostic biomarker for CAR T-cell failure in non-Hodgkin lymphoma.Concept: InflaMix uses results from common blood tests to predict survival and treatment response to CAR T-cell therapy.Impact: Resolving inflammation prior to CAR T-cell therapy may improve responses in patients with lymphomas.

Publication Details

Journal
Cancer Discovery
Published
2025-01-01
DOI
https://doi.org/10.1158/2159-8290.cd-rw2025-045
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Common Blood Tests Predict CAR T-cell Therapy Response in Non-Hodgkin Lymphoma

Cancer Discovery
CAR-T cell therapy research
article

Common Blood Tests Predict CAR T-cell Therapy Response in Non-Hodgkin Lymphoma

article en

Abstract

Major Finding: An inflammatory signature is a prognostic biomarker for CAR T-cell failure in non-Hodgkin lymphoma.Concept: InflaMix uses results from common blood tests to predict survival and treatment response to CAR T-cell therapy.Impact: Resolving inflammation prior to CAR T-cell therapy may improve responses in patients with lymphomas.

Cancer Discovery
Good health and well-being
Openalex Percentile: Top 83%
CAR-T cell therapy research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Common Blood Tests Predict CAR T-cell Therapy Response in Non-Hodgkin Lymphoma · Cancer Discovery (2025) | TGRS Research Map | TGRS